Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.37 |
| ▸ | PYGL | P06737 | 3/20 | 0.37 |
| ▸ | PYGM | P11217 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4606849 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL30843231 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL4653458 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL12899847 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL29776749 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL5971391 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL13177330 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL5707581 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL17285835 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL5707577 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160000753-A1 | Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2016-01-07 | — | — | US | disclosed |
| US-20150336981-A1 | MODIFIED POLYPHENOLS AND MODIFIED POLYPHENOL COMPOSITIONS | CELLAROUGE PTY LTD (AU) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000753-A1 | Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof | ATG7, BECN1, ATG4A | PYGB 1148/4885PYGL 2897/4885PYGM 1635/4885 |
| US-20150336981-A1 | MODIFIED POLYPHENOLS AND MODIFIED POLYPHENOL COMPOSITIONS | PGC, COMT, EGLN2 | PYGB 1278/4885PYGL 1081/4885PYGM 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.